Data / Drug companies / Dr. Reddy's Laboratories Inc.
Dr. Reddy's Laboratories Inc.: 106 products in the FDA NDC directory, labeler code 75907
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Dr. Reddy's Laboratories Inc. (labeler code 75907) lists 106 products in the FDA National Drug Code Directory, covering 57 finished drugs by generic name. By type: 80 prescription drugs, 19 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 25, 2026.
The request: Watch Dr. Reddy's Laboratories Inc. (FDA labeler code 75907): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 75907
- Products in commercial distribution
- 106
- Packages
- 151
- Finished drugs by generic name
- 57
- Prescription products
- 80
- Over the counter products
- 19
- Controlled substance products
- Schedule II 6, Schedule III 2, Schedule IV 2
- Flagged as original packager
- 97 of 97 products that carry the flag
- Started marketing in the last 12 months
- 23
- Products with a marketing end date set
- 6
- Earliest marketing start
- October 22, 2021
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 88 | 83% |
| Drugs for further processing | 6 | 5.7% |
| New drug applications (NDA) | 4 | 3.8% |
| Over the counter monograph drugs | 4 | 3.8% |
| Authorized generics (NDA) | 3 | 2.8% |
| Export only | 1 | 0.9% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 80 | 75.5% |
| Over the counter drugs | 19 | 17.9% |
| Drugs for further processing | 6 | 5.7% |
| Bulk ingredients | 1 | 0.9% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 25 | 23.6% |
| Capsule | 14 | 13.2% |
| Kit | 10 | 9.4% |
| Capsule, extended release | 8 | 7.5% |
| Solution/ drops | 7 | 6.6% |
| Injection, solution | 5 | 4.7% |
| Tablet, film coated | 4 | 3.8% |
| Capsule, liquid filled | 4 | 3.8% |
| Gum, chewing | 4 | 3.8% |
| Tablet, film coated, extended release | 4 | 3.8% |
| Patch, extended release | 3 | 2.8% |
| Tablet, coated | 3 | 2.8% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Acetaminophen Aspirin Caffeine | 75907-432 | Tablet | Generic drugs (ANDA) | September 25, 2026 |
| Acetaminophen Diphenhydramine HCL | 75907-431 | Tablet | Over the counter monograph drugs | September 25, 2026 |
| Allergy Relief | 75907-434 | Tablet | Generic drugs (ANDA) | July 1, 2026 |
| Acetaminophen Extra Strength | 75907-433 | Tablet | Over the counter monograph drugs | July 1, 2026 |
| 8 HR Arthritis Pain | 75907-430 | Tablet, extended release | Generic drugs (ANDA) | July 1, 2026 |
| Acetaminophen Extra Strength | 75907-429 | Tablet | Over the counter monograph drugs | July 1, 2026 |
| Ibuprofen | 75907-428 | Tablet, coated | Generic drugs (ANDA) | July 1, 2026 |
| Bosutinib | 75907-405 | Tablet, film coated | Generic drugs (ANDA) | June 12, 2026 |
| Olopatadine Hydrochloride Ophthalmic Solution | 75907-285 | Solution/ drops | Generic drugs (ANDA) | April 15, 2026 |
| Olopatadine hydrochloride | 75907-285 | Solution/ drops | Drugs for further processing | February 2, 2026 |
| Zoliflodacin | 75907-374 | Granule | Export only | February 1, 2026 |
| Eye Allergy Itch Relief | 75907-343 | Solution | Generic drugs (ANDA) | January 15, 2026 |
| Sertraline Hydrochloride | 75907-311 | Capsule | Generic drugs (ANDA) | January 15, 2026 |
| Sertraline Hydrochloride | 75907-310 | Capsule | Generic drugs (ANDA) | January 15, 2026 |
| Metoprolol succinate | 75907-347 | Tablet, film coated, extended release | Generic drugs (ANDA) | January 13, 2026 |
| Metoprolol succinate | 75907-346 | Tablet, film coated, extended release | Generic drugs (ANDA) | January 13, 2026 |
| Metoprolol succinate | 75907-345 | Tablet, film coated, extended release | Generic drugs (ANDA) | January 13, 2026 |
| Metoprolol succinate | 75907-344 | Tablet, film coated, extended release | Generic drugs (ANDA) | January 13, 2026 |
| Gas Relief | 75907-365 | Capsule, liquid filled | Over the counter monograph drugs | December 26, 2025 |
| Deferiprone | 75907-349 | Tablet, coated | Generic drugs (ANDA) | December 15, 2025 |
| Deferiprone | 75907-348 | Tablet, coated | Generic drugs (ANDA) | December 15, 2025 |
| Sodium Nitroprusside | 75907-290 | Injection, solution | Generic drugs (ANDA) | December 1, 2025 |
| Methamphetamine Hydrochloride | 75907-094 | Tablet | Generic drugs (ANDA) | November 7, 2025 |
| Carmustine | 75907-327 | Kit | Generic drugs (ANDA) | October 1, 2025 |
| Phenylephrine hydrochloride | 75907-324 | Solution/ drops | Generic drugs (ANDA) | September 30, 2025 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.